Summary The effect of tamoxifen upon cellular DNA ploidy in carcinoma of the breast was assessed by flow cytometry (FCM), in a prospective group of 77 patients with primary operable disease. Each had a needle biopsy at the outpatient visit for diagnosis and FCM analysis, and definitive surgery was performed a median of 8 days later. Forty received tamoxifen during this period -40mgqds loading dose for 24h, followed by 20mg daily until the day of operation: 37 patients received no therapy. The DNA histogram from the needle biopsy was compared with that obtained from the resected tumour for each individual. There was little change between the pair of histograms from tumours from the untreated patients. In those who had received tamoxifen the most consistent effect was a marked reduction in the magnitude of the 'tetraploid' peak in tetraploid or near-tetraploid tumours with DNA indices 1.8-2.0. There was little change in diploid or 'other DNA-aneuploid' tumours. In tetraploid tumours (DNA index of 2.0) the percentage of nuclei in the diploid S phase was significantly related to the percentage of nuclei in the diploid G2+M/tetraploid Gl peak (P<0.003, unpaired t test). These data suggest that an effect of tamoxifen can be demonstrated by FCM upon tumours exhibiting a tetraploid or near-tetraploid DNA content. It is possible that tetraploid or neartetraploid human mannary tumours may be a distinct group of endocrine responsive tumours within the overall group of aneuploid tumours, and that the majority are probably derived from the diploid population rather than being a true aneuploid population.
It is well established that well-differentiated carcinomas generally have a better prognosis than poorly-differentiated tumours of comparable stage. Flow cytometry (FCM) has been used in many studies to evaluate differentiation by means of estimating cellular DNA ploidy, but the findings from reports which compare diploid tumours with the total aneuploid group are confusing (Moran et al., 1984; Kute et al., 1985; Stuart-Harris et al., 1985) . There is presently little, if any, utility for flow cytometry in the clinical management of carcinoma of the breast. In the preceding paper we have reported that patients with advanced carcinoma of the breast who had diploid or 'tetraploid' tumours, fared better than those with 'other DNA-aneuploid' tumours (Baildam et al., 1987) . This benefit was manifested in a significantly higher rate of response to endocrine treatment, a significantly longer time to progression whilst on therapy, and a longer period of survival after the start of endocrine therapy.
Response to treatment is probably dependent to an extent on cell cycle kinetics, which may be evaluated by DNA ploidy estimation (Fossa et al., 1984) . Some data derived from experimental studies indicate that changes in DNA histograms may occur after hormonal manipulation (Osborne et al., 1983; Sutherland et al., 1983; Brunner et al., 1983) . The aim of this prospective study was to investigate whether any effect of tamoxifen in vivo could be demonstrated on the DNA histograms derived from primary human mammary carcinomas.
Patients and methods

Patients
This study was with a primary operable carcinoma of the breast over a twelve month period from 1984 to 1985 (n=77) . A Trucut needle biopsy was performed on each patient for confirmation of diagnosis at the first visit; and arrangements were made for individual hospital admissions for definitive surgery, wherever possible the following week. Forty patients were then given tamoxifen 40mgqds for one day (loading dose) followed by 20mg each day until the day of operation, a median of 8 days later: 37 were controls and were given no therapy in the period between biopsy and operation. The original aim of this study was to demonstrate any possible effect of tamoxifen on the concentrations of progesterone receptor within each tumour; this was explained to every patient and consent was obtained. The clinical characteristics for the patients are listed in Table I. A portion of tumour from needle biopsies as well as resected tumours was stored in liquid nitrogen for subsequent receptor assays.
Flow cytometry
Paraffin-embedded, formalin-fixed material was used throughout. Sections were taken from adjacent areas on the blocks for confirmation of histopathological diagnosis. In Trucut biopsies 3 or 4 sections of 30,um thickness were used to ensure sufficient numbers of nuclei for analysis. Single 30,um sections were used from the resected samples. Nuclear suspensions for FCM analysis were prepared by the method of Hedley, but with a slight modification of the fluorochrome. We used propidium iodide whereas the published method employed DAPI (Hedley et al., 1983 
Analysis of histograms
Half peak coefficient of variability (CV) was evaluated for each histogram and ranged from 2-9% (median 5%). Analysis was repeated for any histogram with a CV greater than 10%. For the description of aneuploid peaks, DNA indices were used, calculated as the ratio of the aneuploid peak channel to the first peak, which was considered to be diploid or near diploid and was present on each histogram (Coulson et al., 1984) . Diploid tumours were defined by DNA index 1.0-1.1, tetraploid tumours by a diploid G2 + M/tetraploid G1 > 10% nuclei analysed, together with a tetraploid G2+M peak. Histograms were grouped together as diploid (DNA index 1.1), 'tetraploid' (near-tetraploid with DNA index 1.8-1.9, and tetraploid with DNA index 2.0), and 'other DNA-aneuploid' (DNA indices 1. fractions in 49 DNA histograms which had tetraploid DNA peaks (DNA index 2.0) were analysed by well recognised methods of computation (Dean et al., 1983; Blackledge et al., 1980) .
Steroid hormone receptor assays
Tissue from needle biopsies and from resected tumours removed at operation were stored in liquid nitrogen until the time of receptor assay. Each frozen sample was homogenised by means of a teflon capsule and tungsten ball which had both been pre-cooled with liquid nitrogen, and subjected to the action of a dismembranator for 30 sec. The resulting powder was suspended in buffer (10mM Tris-HCl pH 7.4 with 1mM EDTA, 0.5mM dithiothreitol and 30% v/v glycerol), and centrifuged at 1,000g for 10min at 4°C to remove nuclei, fat, and any debris.
For all samples the method of isoelectric focusing (IEF) was employed (Lloyd et al., 1982; Harland et al., 1983) . Any positive value with an appropriate isoelectric point (pl) was taken to indicate a positive receptor value. The total protein content was measured by the BCA protein assay reagent (Pierce UK Ltd., Cambridge, UK).
Tamoxifen estimations
As a check that patients were taking tamoxifen, a preoperative blood sample was taken for assay of serum tamoxifen concentrations. This was performed by means of a modification of a previously published method (Golander & Sternson, 1980 
Results
The paraffin-embedded Trucut needle biopsy cores provided consistently good tissue for analysis. The proportions of DNA ploidy groups in histograms from the Trucut biopsies for all 77 patients were compared with the findings for tumours from patients with advanced disease in the study described previously (Table II) , (Blaildam et al., 1987) . The proportion of 'other DNA aneuploid' tumours was 28% for both studies. There was a higher incidence of tumours with a DNA content of 'tetraploid' in the needle biopsies (44%) than was found in the previous study (34%), and this was reflected in the lower incidence of diploid tumours.
The findings in the Trucut biopsies of patients who were destined to receive tamoxifen were very similar to those found in samples from patients who were not. (Table III) .
In patients who received no treatment with tamoxifen the findings in the resected tumour were essentially similar to those in the Trucut biopsies. The number of nuclear particles in the diploid G2+M or second major peak in each Trucut biopsy, was compared with the number on that same peak from the analysis of its resected tumour. There were some minor differences (Figure 1 ). One diploid tumour produced a significant 'tetraploid' peak in the second sample (diploid 'G2+M'>10% of total cell population, plus a tetraploid G2 + M peak), and there were minor changes in 'other DNA-aneuploid tumours. When tumours with 'tetraploid' DNA content were considered there were differences apparent between the Trucut biopsies and the resected tumours. In 6 tumours the number of nuclei in the 'tetraploid' peak increased, in 4 it decreased, and in 5 it remained the same. But these differences failed to achieve statistical significance.
In patients treated with tamoxifen the results were similar for diploid and 'other DNA-aneuploid' tumours. When tumours with 'tetraploid' DNA peaks were considered there were changes between the two histograms. In these patients there was a striking difference between the 'tetraploid' peaks obtained from the needle biopsy and those from the resected tumours, and an example of the change is shown (Figure 2 ). The 'tetraploid' peak was greatly diminished in a majority of tumours, and 15 of the 20 tumours were of diploid histogram pattern in the second sample (Figure 3 ). These differences were highly significant (Chi-square = 20.97, P< 0.000).
The number of nuclei in the diploid G2 + M or second major peak in each resected tumour, was expressed as a ratio to the same peak in the Trucut biopsy (Figure 4 ). In patients who had not received tamoxifen the median ratios for all three tumour groups were around unity, reflecting minimal change only between each pair of samples. For patients who had received tamoxifen, the median ratios for diploid and 'other DNA aneuploid' tumours were also around unity. In the tumours with a 'tetraploid' peak treated with tamoxifen there was median ratio of 5, reflecting the decrease in the 'tetraploid' peaks. Twelve of the fifteen originally 'tetraploid' tumours which became diploid in the resected tumour were positive for ER and for PR ( Figure 5 ). Two 'tetraploid' tumours in the group which was not treated with tamoxifen also become diploid in the resected specimen. Both were positive for ER and for PR. There was a very low incidence of receptor positivity within the 'multiploid' tumours -3 of 10 were ER positive, and 1 of 10 was PR positive. Diploid S phase fraction and 'tetraploid' peaks The diploid S phase fraction in 40 tumours with a DNA index of 2.0 was estimated by means of a computer program which is in wide use (Fried, 1976; Blackledge et al., 1980) . The diploid S phase fraction was related to the number of nuclei in the diploid G2+M/tetraploid Gl peak for tumours derived both from the advanced study and also from the needle biopsies of the primary operable study. The number of nuclei in the diploid S phase fractions and in the G2+M/tetraploid GI peaks were highly correlated (P< 0.003, unpaired t test). The increase in the mean diploid S phase in shown with increase of the G2+M/tetraploid GI peak relative to the diploid GI peak in DNA histogram patterns ( Figure 6 ). For this calculation the 40 histograms have been supplemented with 9 histograms from tetraploid colonic tumours.
Discussion
Trucut biopsy samples provided adequate tissue for DNA ploidy analysis by flow cytometry: two or three 30 um sections were taken from each sample and it was not difficult to obtain 5,000 nuclei after dissociation of the tissue. It has been estimated that a single 30pm section of tissue 1 cm2 can (Coon et al., 1986) . Thus an average trucut sample (2 x 0.2 x 0.1 cm) could release 2.5 x I05 nuclei from one 30pgm section.
Tamoxifen was given as a loading dose so that therapeutic levels were present at the time of operation, and this was confirmed by measurement of serum drug concentration.
The difficulty of interpretation of a 'tetraploid' peak has been discussed in the preceding study (Baildam et al., 1987) . We found no consistent effect of tamoxifen on diploid and 'other DNA-aneuploid' tumours, but in 'tetraploid' tumours (near-tetraploid and tetraploid) with a significant 'tetraploid' peak (_ 10% nuclei), after tamoxifen in the majority there was a highly significant reduction in the number of nuclei in the 'tetraploid' peak. The possibility that the difference between the two samples might result from heterogeneity of the tumours must be considered, but this seems unlikely because no consistent changes were found in those which were untreated. In previous studies variations in DNA content were not found between primary tumours and axillary metastases (Auer et al., 1984; Erhardt & Auer, 1986a) . Variations within tumours were present in one study in two of eight tumours when multiple biopsies were taken (Prey et al., 1985) , and in another report, in two of seventeen tumours (Erhardt & Auer, 1986b) . It seems unlikely that the reduction of the 'tetraploid' peaks in this study could have resulted from other than a direct or indirect effect of tamoxifen.
This study emphasises the difficulty of interpretation of 'tetraploid' DNA peaks. It is impossible to distinguish by flow cytometry between the relative contribution of diploid G2+M and tetraploid GI nuclei to the peak. It may be postulated that many tumours with apparent 'tetraploid' peaks are essentially diploid tumours with a high proportion of cells partially arrested in the G2+M phases of the cell cycle. These 'tetraploid' cells, if generated from diploid or near-diploid cells, could represent highly dynamic and therefore potentially therapeutically-sensitive cell populations. However, it is also conceivable that in some tumours, the 'tetraploid' population consists of nonmalignant cells (such as adjacent duct epithelium and/or stromal cells) with a high G2M. Inhibition of cell-cycle progression by tamoxifen in Gl (or early G2) would allow the 'tetraploid' population of cells to pass either through mitosis and enter the apparent diploid population, or to die (Taylor et al., 1983a; Brunner et al., 1985) . One study demonstrated that 'tetraploid' peaks in histograms obtained from oestradiol-synchronised MCF-7 cell lines, diminished dramatically after the cultures had been exposed to tamoxifen for sixteen hours (Sutherland et al., 1984) . The correlation between the proportion of cells in diploid S phase and G2 + M in tetraploid tumours with a DNA index of 2.0 supports this suggestion. Further experimental evidence for a diploid-tetraploid interdependence and induced diploid polyploidisation has been reported in cycling cell populations treated with cytostatic agents (Tobey et al., 1978) .
The reason for the postulated block in G2 is not clear. Administration of oestradiol to immune-deprived mice who bear the T61 human mammary cell line results in cessation of tumour growth and a dramatic increase in the number of cells in diploid S and G2 + M, and a concurrent increase in a tetraploid S and G2 + M, described as 'polyploidisation' (Brunner et al., 1983) . It is possible that the 'tetraploid' peaks could be produced by the effect of endogenous oestradiol causing accumulation in G2: such an accumulation could be reversed by tamoxifen. Furthermore the tetraploid G2+M peaks could be the result of 'polyploidisation' of diploid cells.
The diminution of the 'tetraploid' peak in response to tamoxifen is consistent with most of these tumours being endocrine responsive. This hypothesis is supported by the demonstration that patients with advanced disease had a high probability of response to tamoxifen if their primary tumour contained a 'tetraploid' peak (Baildam et al., 1987) .
However, it should be noted that tamoxifen has oestrogenic, as well as antioestrogenic effects in the first few weeks of treatment, which account for flare reactions observed clinically. Oestrogens have been found to produce cell cycle effects in breast cancer patients which are apparently independent of receptor status and perhaps mediated indirectly via an effect on host cells (cf. Conte et al., 1985; Haslam, 1986) .
When the diploid G2 + M was <10%, there was no detectable effect of tamoxifen upon the S or G2 phases of diploid tumours. It is possible that in diploid tumours tamoxifen may inhibit proliferation by an effect in both Gl and G2. This has been suggested previously for MCF-7 cells treated with tamoxifen in vitro, and in the T61 tumours grown in immune-deprived mice (Brunner et al., 1983; Lykkesfeldt et al., 1984; Osborne et al., 1983) .
It cannot be determined at this stage whether clinical response to therapy corresponds to changes in the DNA histograms. Indeed the effect reported here may be completely independent of clinical response and the mechanisms whereby response is produced. We can only reiterate that in our study on advanced disease patients with 'tetraploid' tumours did demonstrate the highest response rates to endocrine manipulation, and did fare better than those with 'other DNA-aneuploid' tumours. 
